Leukemia Clinical Trials in Philadelphia

Showing 361-380 of 814 trials

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

NCT05509855

This study will provide long-term follow-up for patients who have received treatment with WU-CART-007 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of WU-CART-007 for evaluation of delayed adverse events, presence of persisting WU-CART-007 vector sequences, and overall survival and progression-free survival.

T-cell Acute Lymphoblastic LeukemiaT-cell Lymphoblastic Lymphoma

Wugen, Inc.44 participantsStarted Aug 2022

Duarte, California, United States • Los Angeles, California, United States • St Louis, Missouri, United States +2 more locations

COMPLETEDPHASE1/PHASE2< 1 mile

Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

NCT02561455

The purpose of the study was to provide access to continued treatment for those who participated in other Astellas sponsored ASP2215 trials that completed the primary analysis and, had the potential to continue to derive clinical benefit from the treatment with ASP2215, and who did not meet any of the study discontinuation criteria in the present study.

Advanced Solid TumorsAcute Myeloid Leukemia

Astellas Pharma Global Development, Inc.9 participantsStarted May 2016

Phoenix, Arizona, United States • Baltimore, Maryland, United States • New York, New York, United States +4 more locations

COMPLETEDPHASE1/PHASE261 miles

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

NCT03761914

To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.

Acute Myelogenous LeukemiaOvarian CancerColorectal Cancer+2 more

Sellas Life Sciences Group26 participantsStarted Sep 2019

Santa Rosa, California, United States • Whittier, California, United States • Miami, Florida, United States +9 more locations

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Leukemia Trials in Other Cities

DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer

A Study of ZN-c3 in Patients With Ovarian Cancer

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

Milademetan in Advanced/Metastatic Solid Tumors

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

First in Human Study of M1069 in Advanced Solid Tumors

SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas

Stratification of Risks of Conversion of Radiologically Isolated Syndromes (RIS) by Identifying Biomarkers in Serum and Cerebrospinal Fluid.

Other Conditions in Philadelphia